TABLE 3

Observed in vivo parameters for atorvastatin, cerivastatin, and indomethacin in bile duct cannulated and noncannulated rats All data represent individual animals or mean ± S.D. of a minimum of three animals.




Atorvastatin

Cerivastatin

Indomethacin*
Bile duct cannulated
   Cl (ml/min/kg) 43, 43 17 ± 6 0.2, 0.3
   Plasma Css (ng/ml) 370, 420 690 ± 270 4400, 3800
   Liver Css (ng/g tissue) 16,000, 26,000 39,000 ± 8000 920, 920
   Liver/plasma ratio 52, 62 65 ± 37 0.21, 0.24
   Muscle Css (ng/g tissue) 84, 210 270 ± 110 160, 170
   Muscle plasma ratio 0.2, 0.5 0.395 ± 0.001 0.036, 0.046
   Biliary Cl (ml/min/kg) 8.9, 7.1 0.4 ± 0.1 0.001, 0.001
Noncannulated
   Cl (ml/min/kg) 47 ± 8 27 ± 11 0.51 ± 0.04
   Vss (l/kg) 0.5 ± 0.1 3.0 ± 1.9 0.19 ± 0.03
   Half-life (h)
1.2 ± 0.5
2.9 ± 0.4
4.6 ± 1.0
  • * Indomethacin was dosed to bile duct cannulated rats by bolus injection and tissue samples taken at 7 h